Kymera Therapeutics Files 8-K
Ticker: KYMR · Form: 8-K · Filed: May 9, 2025 · CIK: 1815442
| Field | Detail |
|---|---|
| Company | Kymera Therapeutics, Inc. (KYMR) |
| Form Type | 8-K |
| Filed Date | May 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations, sec-filing
Related Tickers: KYMR
TL;DR
Kymera filed an 8-K on 5/9/25 covering financials and operations.
AI Summary
Kymera Therapeutics, Inc. filed an 8-K on May 9, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these standard sections.
Why It Matters
This 8-K filing indicates that Kymera Therapeutics is providing updates on its financial condition and operations, which could contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting routine financial and operational disclosures without specific new material events.
Key Players & Entities
- Kymera Therapeutics, Inc. (company) — Registrant
- May 9, 2025 (date) — Date of earliest event reported
- 001-39460 (other) — SEC File Number
- 81-2992166 (other) — I.R.S. Employer Identification No.
- 500 North Beacon Street, 4th Floor, Watertown, Massachusetts 02472 (address) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific figures are not detailed in the provided header information.
What is the primary purpose of this 8-K filing for Kymera Therapeutics?
The primary purpose is to report on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits as of May 9, 2025.
When was this 8-K report filed?
The report was filed on May 9, 2025.
What is Kymera Therapeutics' principal executive office address?
Kymera Therapeutics' principal executive offices are located at 500 North Beacon Street, 4th Floor, Watertown, Massachusetts 02472.
Does this filing indicate any new material events or strategic changes for Kymera Therapeutics?
The provided header information for this 8-K does not specify any new material events or strategic changes, only the reporting of standard financial and operational sections.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 9, 2025 regarding Kymera Therapeutics, Inc. (KYMR).